摘要
目的观察膀胱腔内细胞过继免疫治疗对膀胱局部免疫功能的影响 ,以探讨一种有效预防浅表性膀胱癌术后复发的新疗法。方法采用盐析法 ,由手术切除的患者自体膀胱肿瘤标本制备膀胱肿瘤可溶性抗原 (BTSA) ,以卡介苗为佐剂 ,共同诱导人外周血单个核细胞成为抗膀胱肿瘤效应细胞 (BT-BAK)细胞。将 BT-BAK细胞应用于肿瘤切除术后浅表性膀胱癌患者的膀胱腔内灌注治疗 ,定期行膀胱镜复查及膀胱粘膜活检 ;采用酶联免疫吸附法测定尿液中细胞因子含量的变化。结果 37例治疗后 ,膀胱粘膜组织学观察显示为轻或中度非特异性炎症性反应 ,仅 1例发现粘膜上皮轻度异型性增生 ,复发率为 2 .7%。治疗后患者尿液中 IL-2、TNF-α及 IFN-γ的水平均较治疗前显著提高。结论 BT-BAK细胞膀胱灌注应用于膀胱癌术后治疗 ,可以有效提高膀胱局部的免疫反应水平 。
Objective To investigate the effectiveness of intravesical adoptive immunotherapy to the local immunoreactions of the bladder mucosa in postoperative patients with superficial bladder cancer.Methods Bladder tumor soluble antigen(BTSA)which was prepared through saltinfiltrating biochemical procedures from autologous bladder tumor,with the adjuvant of calmett Guerin vacine (BCG),induced BT BAK (BTSA and BCG activated Killer) cells from human peripheral blood mononuclear cells(PBMNC).BT BAK cells instillated intravesically into the patients of superficial bladder cancer undergoing surgical operations.During the therapy,the immunological effects of BT BAK cells to the bladder mucosa were monitored through endocytoscope and pathological examinations.The levels of cytokines were also measured with ELISA assays.Results 37 patients were treated with intravesical instillation of BT BAK cells.Pathological studies showed that mild or moderate no specific inflammation was the major change in the bladder mucosa.Only 1 case was found to have a low grade heterogeneity in his bladder mucosa,indicating the recurrence rate of 2.7%.The levels of cytokines IL 2,TNF α and IFN γ in the urine increased significantly.Conclusion BT BAK cells can effectively improve the immunological reactivity of the bladder mucosa with a lower recurrence rate of superficaial bladder cancer
出处
《中国综合临床》
北大核心
2001年第6期454-455,共2页
Clinical Medicine of China
关键词
膀胱癌
膀胱肿瘤可溶性抗原
过继免疫治疗
卡介苗
Bladder cancer
Tumor soluble antigen
Calmett Guerin vacine
Adoptive immunotherapy
